| Literature DB >> 23799947 |
Dongqing Zuo1, Longpo Zheng, Wei Sun, Yingqi Hua, Zhengdong Cai.
Abstract
OBJECTIVE: This study tested the implication of pathologic fractures on the prognosis in stage IIb osteosarcoma.Entities:
Mesh:
Year: 2013 PMID: 23799947 PMCID: PMC3711896 DOI: 10.1186/1477-7819-11-148
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Demographic and characteristic data for 15 cases of pathological fracture associated with stage IIB osteosarcoma
| 1 | Male | 12 | P tibia | II B | classic | LBS | 800 | no | LR | + | | pros | 8 | 7 | good | dead |
| 2 | Female | 15 | P femur | II B | p | LBS | 850 | no | | | | pros | 45 | 45 | good | |
| 3 | Female | 24 | P femur | II B | classic | AMP | 615 | yes | | | | | 39 | 39 | poor | |
| 4 | Male | 18 | P humerus | II B | classic | LBS | 705 | yes | | | | pros | 46 | 46 | good | |
| 5 | Female | 34 | D femur | II B | classic | AMP | 868 | yes | | | | | 44 | 44 | poor | |
| 6 | Male | 19 | D femur | II B | classic | LBS | 920 | no | | | lr | pros | 39 | 39 | good | |
| 7 | Male | 20 | P femur | II B | classic | LBS | 1100 | no | | | | pros | 45 | 45 | good | |
| 8 | Female | 35 | P humerus | II B | classic | AMP | 780 | yes | LR | + | | | 29 | 24 | poor | dead |
| 9 | Female | 22 | D femur | II B | classic | LBS | 850 | no | | | infct | pros | 47 | 47 | good | |
| 10 | Female | 19 | P humerus | II B | classic | LBS | 900 | no | | | | pros | 23 | 22 | poor | dead |
| 11 | Male | 24 | D femur | II B | classic | LBS | 1000 | no | LR | | | pros | 46 | 36 | good | |
| 12 | Male | 42 | P humerus | II B | classic | AMP | 880 | no | | | | | 40 | 38 | poor | dead |
| 13 | Male | 22 | D femur | II B | classic | LBS | 780 | no | | + | brk | pros | 18 | 16 | poor | dead |
| 14 | Male | 18 | P humerus | II B | classic | LBS | 1000 | yes | LR | | | pros | 39 | 34 | good | |
| 15 | Female | 23 | D tibia | II B | classic | AMP | 940 | yes | | + | | | 12 | 11 | poor | dead |
| Sum/Mean | 23.2 | 865.9 | 4 | 4 | 3 | 34.7 | 32.9 | 6 | ||||||||
P type: Pathologic type; classic: Classic osteosarcoma; p: Periosteal osteosarcoma; P: Proximal; D: Distal; AMP: Amputation; LBS: Limb salvage surgery; FP time: Follow-up time; CPL: Complication; RC type: Reconstruction type; infct: Infection; lr: Local recurrence; brk: Breakage; pros: Prosthesis.
Clinical characteristics of the fracture group and non-fracture groups
| Age (mean) | 23.2±8.0 | 21.8±12.2 | 0.69 |
| Stage | IIB | IIB | |
| | | 0.36 | |
| Classic | 93.3% (14) | 98% (49) | |
| Others | 6.7% (1) | 2% (1) | |
| | | 0.99 | |
| Femur | 53.3% (8) | 54% (27) | |
| Tibia | 13.3% (2) | 14% (7) | |
| Humerus | 33.3% (5) | 32% (16) |
Figure 1Localized osteosarcoma complicated by pathologic fracture of the humerus in an 18-year old patient. (a) X-ray of A-P position for patient at presentation; (b) Preoperative MRI indicating extraosseous lesion and undisplaced fracture of the humerus; (c) The resected specimen including the proximal humerus and biceps at the osteotomy level; (d) Reconstruction with semi-shoulder prosthesis; (e) Postoperative X-ray of affected arm.
Surgical data, MTST scores, and clinical outcomes of patients with or without pathologic fracture
| | | | |
| Amputation | 5 | 4 | |
| (Mean MTST score) | 18.8±3.5 | 21.2±4.6 | 0.040 |
| Limb salvage | 10 | 46 | |
| (Mean MTST score) | 23.5±3.9 | 25.3±4.2 | 0.219 |
| | | | |
| Pseudocapsule rupture | 14 (93.3%) | 5 (10.0%) | <0.001 |
| Wide margin | 13 (86.7%) | 44 (88.0%) | 0.890 |
| Other margins | 2 (13.3%) | 6 (12.0%) | |
| | | | |
| Recurrence | 4 (26.7%) | 7 (14.0%) | 0.25 |
| Complications | 3 (20%) | 6 (12.0%) | 0.43 |
| Metastasis | 4 (26.7%) | 16 (32.0%) | 0.69 |
| 3-year DFS | 53.3% | 66.5% | 0.25 |
| 3-year OS | 66.7% | 75.3% | 0.52 |
MSTS: Musculoskeletal Tumor Society; DFS: Disease-free survival; OS: Overall survival.
Figure 2Overall and disease-free survival percentage by month. (a) Kaplan-Meier survival curve indicates no statistical difference in the overall survival rate between patients in the study and control groups; (b) Kaplan-Meier survival curve indicates no statistical difference in disease-free survival rate between patients in the study and control groups.